B. Riley Predicts Harrow's FY2025 Earnings (NASDAQ:HROW)

Key Points

• B. Riley has raised its FY2025 earnings per share estimate for Harrow, Inc. from $0.88 to $0.93, maintaining a "Buy" rating and a target price of $70.00.
• Harrow recently announced quarterly earnings of $0.24 per share, significantly exceeding analysts' expectations of $0.01, with a revenue of $63.74 million.
• Analysts show strong confidence in Harrow's stock, with multiple firms raising their price targets, and the stock holding a consensus rating of Moderate Buy with a target of $65.33.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Investment analysts at B. Riley upped their FY2025 earnings per share estimates for Harrow in a note issued to investors on Tuesday, September 23rd. B. Riley analyst M. Mamtani now anticipates that the company will post earnings per share of $0.93 for the year, up from their prior forecast of $0.88. B. Riley currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow's FY2027 earnings at $4.16 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.23. The business had revenue of $63.74 million for the quarter, compared to analyst estimates of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS.

HROW has been the subject of several other reports. HC Wainwright lifted their target price on Harrow from $60.00 to $64.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Cantor Fitzgerald assumed coverage on Harrow in a report on Friday, July 11th. They set an "overweight" rating and a $76.00 price target for the company. BTIG Research lifted their price target on Harrow from $62.00 to $63.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. William Blair assumed coverage on Harrow in a report on Tuesday, June 10th. They set an "outperform" rating for the company. Finally, Craig Hallum lifted their price target on Harrow from $54.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, Harrow has an average rating of "Moderate Buy" and a consensus price target of $65.33.

Harrow Stock Up 6.0%

HROW stock opened at $48.85 on Wednesday. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. The business has a 50 day moving average price of $37.78 and a two-hundred day moving average price of $30.92. The company has a market cap of $1.81 billion, a price-to-earnings ratio of -195.40 and a beta of 0.33. Harrow has a twelve month low of $20.85 and a twelve month high of $59.23.

Institutional Trading of Harrow

Large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in Harrow in the fourth quarter worth $25,000. Quarry LP purchased a new position in shares of Harrow in the first quarter valued at $32,000. Raymond James Financial Inc. purchased a new position in shares of Harrow in the second quarter valued at $48,000. Tower Research Capital LLC TRC grew its position in shares of Harrow by 345.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company's stock valued at $103,000 after purchasing an additional 2,615 shares in the last quarter. Finally, State of Wyoming purchased a new position in shares of Harrow in the first quarter valued at $97,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.